FGFR1 and adrenal cortex carcinoma: In a phase II study, 35 patients with progressive ACC were treated with dovitinib, a small molecular inhibitor of FGFR1, and it was found that 6% of patients showed a partial response while 65% exhibited stable disease; however, progression-free survival (8.2 months) was more favorable when compared with other molecular target agents [93].